Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Exelixis, Inc. (EXEL - Free Report) was a big mover last session, as its shares rose over 11% on the day. The stock price was driven by positive phase 3 trial results for the company’s renal cell carcinoma treatment. This also led to far more shares changing hands than in a normal session. Yesterday’s rally continues the recent uptrend for the company, as the stock is now up over 48% in the past one-month time frame.
Over the last 30 days, the company witnessed three positive and one negative estimate revision while the Zacks Consensus Estimate moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
Exelixis currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy).
Is EXEL going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>